No usable source links are available for this idea. Its signal notes and scores need independent verification.
With KIST designating AI virtual cells and RNA therapeutics among its top 10 technologies, BioAI publications are surging (30%+ annual growth). Researchers at bio Startups and institutes spend 2–4 hours analyzing each paper, manually extracting and comparing key experimental conditions (cell lines, model architecture, dataset size, performance metrics). For researchers tracking 50–100 papers per month, this means 100+ hours of unproductive work monthly.
(1) Upload BioAI paper PDFs to auto-extract experimental conditions, results, and model specs into structured tables, (2) Auto-compare against existing extracted data to determine SOTA (State of the Art) update status, (3) Weekly arXiv/PubMed new paper alerts with keyword matching and summaries — delivered as a SaaS.
| N Novelty | 1-5 | How uncommon the service is in market context. |
| U Urgency | 1-5 | How urgently users need this problem solved now. |
| M Market | 1-5 | Market size and growth potential from proxy indicators. |
| R Realizability | 1-5 | Buildability for a small team with realistic constraints. |
| V Validation | 1-5 | Validation signal quality from competition and demand data. |
| Tech Complexity | / 40 | Difficulty of core implementation stack. |
| Data Availability | / 25 | Practical availability and cost of required data. |
| MVP Timeline | / 20 | Expected time to ship a usable MVP. |
| API Bonus | / 15 | Bonus for viable public API leverage. |
| Competition | / 20 | Signal quality from competitor landscape. |
| Market Demand | / 20 | Demand proxies from search and mention patterns. |
| Timing | / 20 | Fit with current shifts in tech, behavior, and regulation. |
| Revenue Signals | / 15 | Reference evidence for monetization viability. |
| Pick-Axe Fit | / 15 | How well the concept serves participants in a trend. |
| Solo Buildability | / 10 | Practicality for lean-team implementation. |